Alembic gains 31% so far in September on stake purchase by promoter

As of June 30, 2020, the total promoter holding in Alembic stood at 69.57 per cent, up 195 basis points (bps) from 67.62 per cent at the end of March quarter.

stake, share, investment, equity, shareholder, promoter, banks, disinvestment, markets, returns, stocks,diversification
Alembic is engaged in pharmaceuticals, real estate, and ower assets businesses.
SI Reporter Mumbai
2 min read Last Updated : Sep 10 2020 | 12:09 PM IST
Shares of Alembic surged 9 per cent to hit a 52-week high of Rs 111.80 on the BSE on Thursday. The stock has gained over 30 per cent so far in September after the promoter group company Nirayu Limited bought an additional nearly 1 per cent stake in the company via open market. The stock has surged 31 per cent in the past eight trading days, as compared to a 0.17 per cent decline in the S&P BSE Sensex.

Between September 2, 2020, and September 4, Nirayu Limited, a promoter group company, purchased 1.56 million equity shares, representing 0.61 per cent stake of Alembic, from the open market, the exchange data shows. The names of sellers were not ascertained immediately.

As of June 30, 2020, the total promoter holding in Alembic stood at 69.57 per cent, up 195 basis points (bps) from 67.62 per cent at the end of March quarter.

Alembic is engaged in pharmaceuticals, real estate, and power assets businesses. The company is engaged in the manufacturing and marketing of fermentation and chemistry-based Active Pharmaceuticals Ingredients (API). The Company is also engaged in research and development activity at Vadodara.

It has also given certain commercial properties on lease basis to various tenants. It is also engaged in power generation through Co-Generation with plants of total of 11 MW and wind power with 4 Windmills of total 5 MW.

At 10:44 am, the stock was trading 8 per cent higher at Rs 110 on the BSE, as compared to a 1 per cent rise in the S&P BSE Sensex. The counter has seen huge trading volumes with a combined 2.4 million equity shares changing hands on the NSE and BSE so far.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :Buzzing stocksMarketsPharma stocks

Next Story